<DOC>
	<DOCNO>NCT02124174</DOCNO>
	<brief_summary>Phase II trial combine azacitidine valproic acid maintenance therapy post allogeneic stem cell transplantation patient high-risk MDS/AML . We hypothesize add valproic acid azacitidine improve outcome via direct anti-tumor immunologically mediate antitumor response alloreactive donor lymphocyte , additive effect extend 1 year survival patient high-risk AML/MDS hematopoietic stem cell transplant . Based aforementioned data US Department Health Human Services , standard 1 year survival AML stem cell transplant near 40 % . We hypothesize valproic acid azacitidine prolong survival , 1 year survival goal 60 % . In addition assess 1 year survival , secondary objective assess progression-free survival , relapse , toxicity . The primary toxicity endpoint cytopenias infection .</brief_summary>
	<brief_title>Vidaza Valproic Acid Post Allogeneic Transplant High Risk AML MDS</brief_title>
	<detailed_description>To assess combination valproic acid azacitidine prevent relapse patient high-risk Acute Myeloid Leukemia ( AML ) myelodysplastic syndrome ( MDS ) allogeneic stem cell transplant . The primary objective study determine 1 year overall survival combine valproic acid ( VPA ) 5-azacytidine ( 5-aza ) . To assess effect add valproic acid azacitidine patient high-risk Acute Myeloid Leukemia ( AML ) myelodysplastic syndrome ( MDS ) allogeneic stem cell transplant follow endpoint</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>1 . All allograft patient &gt; 2 year age . 2 . Patients one follow malignancy : . Patients refractory relapse : acute myelogenous leukemia ( AML ) ( include inv16 , ( 8 ; 21 ) ( 15 ; 17 ) ) high risk myelodysplastic syndrome ( MDS ) ( define bone marrow blast &gt; = 5 % ) eligible . Patients may remission time entry . 3 . Patients adequate organ function performance status criterion measure : 1 . Karnofsky score great equal 70 % Performance status &lt; = 2 Eastern Cooperative Oncology Group ( ECOG ) scale 2 . Adequate liver function ( bilirubin &lt; 2mg/dL , serum glutamate pyruvate transaminase &lt; 3 * ULN ) renal function ( creatinine &lt; 2mg/dL ) 4 . Signed informed consent indicate patient aware investigational nature study accordance regulation Loyola University Medical Center 5 . Patients must undergo allogeneic stem cell transplant within 4060 day start treatment selfsufficient caloric intake along active graft vs. host disease 1 . Nursing pregnant female exclude . 2 . Active uncontrolled infection cause patient exclude . 3 . Patients already receive valproic acid receive anticonvulsant exclude . 4 . Low risk AML complete remission 1 , candidate study . 5 . Patients absolute neutrophil count less 1500 exclude 6 . Patients platelets less 50,000 exclude 7 . Children le 2 year age exclude due increase hepatotoxicity valproic acid age group</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>acute myelogenous leukemia ( AML )</keyword>
	<keyword>myelodysplastic syndrome ( MDS )</keyword>
</DOC>